检索结果-内蒙古大学图书馆

Characteristics of circulating γ δ T Cells from individuals chronically infected with Hepatitis C Virus (HCV):an association between V δ 2 Subtype and liver injury associated with HCV infections

Characteristics of circulating γ δ T Cells from individual...

引用

第三届全国病毒性肝炎慢性化重症化基础与临床研究进展学术会议

作者： Wenwei Yin Qiongfang Zhang Hong Ren Dazhi Zhang Department of Infectious Diseases Institute for Viral Hepatitis Key Laboratory of Molecular Biology for Infectious Diseases Ministry of Education The Second Affiliated Hospital of Chongqing Medical University Chongqing China.400016

来源：评论

学校读者我要写书评

暂无评论

HBV相关肝衰竭合并侵袭性肺曲霉菌病的临床特点与转归

HBV相关肝衰竭合并侵袭性肺曲霉菌病的临床特点与转归

引用

第三届全国病毒性肝炎慢性化重症化基础与临床研究进展学术会议

作者：王玮赵彩彦王亚东尹洪竹刘英辉周俊英河北医科大学第三医院感染科

目的:探讨HBV相关肝衰竭合并侵袭性肺曲霉菌病的临床特征、危险因素、诊治及预后。方法:采用病例对照研究的方法,回顾性分析43例HBV相关肝衰竭合并侵袭性肺曲霉菌病患者的临床特征、危险因素、诊治经过、预后及转归等,并随机选取同期住... 详细信息

目的:探讨HBV相关肝衰竭合并侵袭性肺曲霉菌病的临床特征、危险因素、诊治及预后。方法:采用病例对照研究的方法,回顾性分析43例HBV相关肝衰竭合并侵袭性肺曲霉菌病患者的临床特征、危险因素、诊治经过、预后及转归等,并随机选取同期住院的43例HBV相关肝衰竭合并单纯细菌感染患者以及43例未合并感染的HBV相关肝衰竭患者作为对照。结果:HBV相关肝衰竭患者合并侵袭性肺曲霉菌病的发生率逐年升高(P<0.0001);合并感染的HBV相关肝衰竭患者PTA和PLT显著下降,MELD评分升高,尤以IPA组患者为著,合并IPA前后的对比结果亦是如此;IPA组患者的年内病死率为100%,明显高于单纯细菌感染组,二者均高于未合并感染的对照组;统计结果显示住院时间延长、使用大量抗菌药物、侵入性操作频繁等是HBV相关肝衰竭合并IPA的危险因素。结论:HBV相关肝衰竭患者合并IPA后病情迅速恶化、病死率高、预后差,提高对其早期表现的认知度、及早诊断和进行强有力的抗真菌治疗是提高HBV相关肝衰竭合并IPA患者生存率的有效方法。

关键词：侵袭性肺曲霉菌病临床特征 HBV 肝衰竭临床特点

来源：评论

学校读者我要写书评

暂无评论

第三届病鬌性肝炎慢性化、重症化基础与临床研究进展学术会议征文通知

引用

中华肝脏病杂志 2013年第6期 472页

由中华医学会感染病学分会病毒性肝炎学组主办,第三军医大学西南医院承办的"第三届病毒性肝炎慢性化、重症化基础与临床研究进展学术会议",将于2013年11月在美丽的山城重庆召开。会议旨在国内夕卜专家和同行就病毒性肝炎慢性...

由中华医学会感染病学分会病毒性肝炎学组主办,第三军医大学西南医院承办的"第三届病毒性肝炎慢性化、重症化基础与临床研究进展学术会议",将于2013年11月在美丽的山城重庆召开。会议旨在国内夕卜专家和同行就病毒性肝炎慢性化、重症化基础与临床研究进展相互交流、沟通’取长补短,建立基础合作关系,充分利用资源’规范临床诊断治疗。会议将设专题报告、大会发言和书面交流三种形式,特别邀请国内感染病学和肝病学等领域的知名专家,就有关专题进行交流,热烈欢迎相关领域各级临床医师和基础研究人员踊跃投稿并参加会议交流,与会者授予全国继续教育学分。

关键词：

来源：评论

学校读者我要写书评

暂无评论

Enhanced expression of potassium ion channel gene KCNJ15 is associated with Acute-on-chronic Hepatitis B liver failure

Enhanced expression of potassium ion channel gene KCNJ15 is ...

引用

第三届全国病毒性肝炎慢性化重症化基础与临床研究进展学术会议

作者：朱琳 Tao Chen Daqin Xu Li Song Xiaoping Luo Qin Ning Institute and Department of Infectious Disease Tongji hospital of Tongji Medical CollegeHuazhong University of Science and Technology Department of Pediatrics Tongji hospital of Tongji Medical CollegeHuazhong University of Science and Technology

Increased KCNJ15 expression has been found in patients with hepatitis B virus （HBV）-induced Acute-on-chronic liver failure（HBV-ACLF） in our previous gene microarray study. However,the mechanism underlying the enhanced expression of KCNJ15 in patients with HBV-ACLF remains *** this study,we further investigate the up-regulated KCNJ15 and its possible regulatory mechanisms in HBV induced liver *** expression of KCNJ15 was studied in patients with HBV-ACLF on both mRNA and protein levels in peripheral blood mononuclear cells（PBMC） and liver tissue,while the function of KCNJ15 was further determined in Jurkat cells in vitro by transfection of a human KCNJ15 expression *** results showed that KCNJ15 was over-expressed on PBMCs and hepatic infiltrating lymphocytes from HBV-ACLF ***,KCNJ15 had an abundant expression in peripheral and hepatic CD4T cells in patients with *** the supernatant of KCNJ15 over-expressed Jurkat cells,increased IL-17A secretion was observed,which was involved with elevated intracellular calcium *** data suggested KCNJ15 may contribute to liver injury through IL-17A production in HBV induced liver ***,we also provide a potential susceptible gene for patients with HBV-ACLF.

关键词： KCNJ15 virus induced liver injury acute on chronic liver failure hepatitis B CD4+ T cell IL-17 calcium

来源：评论

学校读者我要写书评

暂无评论

Nucleoside Analogs Prevent Disease Progression in HBV-Related Acute-on-Chronic Liver Failure:Validation of the TPPM Model

Nucleoside Analogs Prevent Disease Progression in HBV-Relate...

引用

第三届全国病毒性肝炎慢性化重症化基础与临床研究进展学术会议

作者：马科 Junshuai Wang Meifang Han Wei Guo Jiaquan Huang Daofeng Yang Xiping Zhao Jiangxin Song Deying Tian Junying Qi Yuancheng Huang Qin Ning Department and Institute of Infectious Disease Tongji Hospital of Tongji Medical CollegeHuazhong University of Science and Technology

Background and aims Hepatitis B related acute-on-chronic liver failure(HBV-ACLF) has a poor prognosis with very high *** in nucleoside analogues treated patients with HBV-ACLF is *** study aimed to evaluate the efficacy and safety of Entecavir, Lamivudine and Telbivudine in treating patients with HBV-ACLF and to validate TPPM model in these patients. Methods In this retrospective study,we enrolled 283 patients with HBV-ACLF(100 treated with Entecavir,98 treated with Lamivudine and 85 treated with Telbivudine).There were no significant differences in baseline clinical and virological characteristics between patients treated with Entecavir,Telbivudine or Lamivudine. Results There were no significant differences in the 4 and 12-week survival rates of Entecavir, Telbivudine and Lamivudine-treated patients(79.00%,81.18%,and 86.73%,respectively at 4 weeks and 67.00%,65.88%,and 73.47%,respectively at 12 weeks).Patients in all three groups achieved an improvement of MELD *** the Hosmor and Lemeshow test,the validation of TPPM for HBV-ACLF demonstrated a good degree of fit with disease *** on this unique group of patients,the TPPM with an AUC of 0.787 was superior to MELD which had an AUC of 0.736 in the prediction of 12-weeks *** had an AUC of 0.733 and MELD had an AUC of 0.672 in the prediction of 4-weeks *** a cutoff of 0.22 for 12-weeks mortality prediction by TPPM,the positive predictive value was 49.66%,with a negative predictive value of 89.55%. Conclusion Nucleotide analogs including Entecavir,Lamivudine and Telbivudine treatment prevented disease progression and increased the survival of patients with *** of the established TPPM scoring system in this study confirmed its superior predictive value for HBV-ACLF patients when compared with MELD.

关键词： HBV Nucleoside Analogs Prevent Disease Progression in HBV-Related Acute-on-Chronic Liver Failure:Validation of the TPPM Model

来源：评论

学校读者我要写书评

暂无评论

拉米夫定联合乙型肝炎免疫球蛋白预防肝移植后乙肝病毒复发的系统评价

拉米夫定联合乙型肝炎免疫球蛋白预防肝移植后乙肝病毒复发的系统...

引用

第三届全国病毒性肝炎慢性化重症化基础与临床研究进展学术会议

作者：江自成江建宁广西医科大学第一附属医院感染性疾病科

目的:评价拉米夫定(1amivudine,LAM)联合乙型肝炎免疫球蛋白(hepatitis Bimmunoglobulin,HBIG)预防肝移植后乙肝病毒复发的价值.方法:计算机检索Medline(Ovid)、PubMed、Embase、CENTRAL(Cochrane Central Registerof Controlled Trails)、中国生物医学文献数据库(CBM)、清华同方数据库(CNKI)、维普中文科技期刊数据库(VIP)关于LAM联合HBIG与LAM单用预防肝移植后乙肝病毒复发的随机双盲对照、非随机同期对照及病例对照研究;截止至2008年12月,两名研究者独立按cochrane系统评价方法选择试验、提取资料,计算各个结局指标的效应量,采用Revman5.0.18软件进行meta分析。结果:共11项研究符合纳入标准,均为非随机同期对照试验,共1421例患者,其中LAM联合HBIG组1035例,LAM单用组386例。LAM联合HBIG治疗组与单用LAM治疗组预防肝移植后乙肝病毒复发结果的比较如下①减少乙肝病毒复发风险达73%(RR=0.27,95%CI:0.20-0.37,p<0.00001)②减少乙肝病毒YMDD变异风险达72%(RR=0.28,95%CI:0.15-0.53,p=0.00001)③减少乙肝病毒复发所致的死亡风险达79%(RR=0.21,95%CI:0.09-0.49,p=0.0003)④受者和移植物总的生存率两组相似(RR=1.03,95%CI:0.95-1.11,p=0.51)和(RR=1.04,95%CI:0.97-1.12,p=0.26)。结论:现有研究显示LAM联合HBIG治疗比LAM单用可明显减少肝移植后乙肝病毒复发、发生YMDD变异及乙肝病毒复发所致的死亡风险。LAM联合HBIG是预防肝移植后乙肝病毒复发的有效措施。

关键词：乙肝病毒 LAM 乙型肝炎免疫球蛋白拉米夫定肝移植系统评价

来源：评论

学校读者我要写书评

暂无评论

肝病患者感染病原菌分布及耐药性

肝病患者感染病原菌分布及耐药性

引用

第三届全国病毒性肝炎慢性化重症化基础与临床研究进展学术会议

作者：丁胜楠许建成陈玉坤牛俊奇吉林大学第一医院肝病科

目的分析肝病患者感染病原菌分布及耐药情况,为临床治疗提供参考。方法:对2010年1月至2012年12月肝病科检出菌株1231株的资料作回顾性分析,病原菌的鉴定采用梅里埃公司VITEK-2compact系统,药敏试验采用纸片扩散法。结果标本主要来源于... 详细信息

目的分析肝病患者感染病原菌分布及耐药情况,为临床治疗提供参考。方法:对2010年1月至2012年12月肝病科检出菌株1231株的资料作回顾性分析,病原菌的鉴定采用梅里埃公司VITEK-2compact系统,药敏试验采用纸片扩散法。结果标本主要来源于腹腔、肺部及血液等。前3位致病菌依次为大肠埃希菌、肺炎克雷伯菌、凝固酶阴性葡萄球菌。腹水感染以大肠埃希菌、草绿色链球菌、枯草芽孢杆菌、肺炎克雷伯菌、表皮葡萄球菌常见(42.1%),革兰阳性球菌占60.0%;胆系感染、血液感染均以革兰阴性杆菌为主(58.7%,73.3%);呼吸道感染以白假丝酵母菌、肺炎克雷伯菌、金黄色葡萄球菌常见(49.2%);胸水感染以凝固酶阴性葡萄球菌多见(30.6%);肠道感染以革兰阳性球菌(24.5%)及真菌(53.1%)多见,而真菌又以白假丝酵母菌为主;大肠埃希菌在尿路感染中占37.9%。常见革兰阴性杆菌对亚胺培南、美罗培南、阿米卡星及头孢西丁、哌拉西林/他唑巴坦、头孢哌酮/舒巴坦的耐药率较低,革兰阳性球菌对万古霉素、替考拉宁、利福平及复方新诺明的耐药率较低。结论提高对肝病患者感染病原菌分布及耐药性认识,合理应用抗生素,降低病死率。

关键词：肝病病原菌耐药

来源：评论

学校读者我要写书评

暂无评论

Effective prevention of perinatal transmission of hepatitis B virus infection using telbivudine in high viral load patients

Effective prevention of perinatal transmission of hepatitis ...

引用

第三届全国病毒性肝炎慢性化重症化基础与临床研究进展学术会议

作者： Quanxin Wu Dengming He Yuming Wang Junnan Li Xiaowen Sun Meiming Pan Shun Tan Yi Zeng Li Li Guohong Deng Hongfei Huang Zehui Yan Institute for Infectious Diseases Department of Gynecology and Obstetrics Southwest Hospital Third Military Medical University Chongqing400038 PR China Changsha First Municipal Hospital Hunan 410005 PR China

来源：评论

学校读者我要写书评

暂无评论

治疗基线HBV BCP区和前C区变异对拉米夫定耐药预测的探讨

治疗基线HBV BCP区和前C区变异对拉米夫定耐药预测的探讨

引用

第三届全国病毒性肝炎慢性化重症化基础与临床研究进展学术会议

作者：胡家光江建宁苏明华葛善飞祝美琴刘志红梁延秀郭稳稳黄小红柳州市人民医院感染科

目的:探讨慢性乙型肝炎患者治疗基线HBV BCP区和前C区基因变异对拉米夫定耐药的影响。方法:收集接受拉米夫定(100/mg)初治2年内耐药的26例(耐药组)和2年内无耐药的16例(对照组)慢性乙型肝炎患者治疗基线的血清标本,采用型特异性多引物... 详细信息

目的:探讨慢性乙型肝炎患者治疗基线HBV BCP区和前C区基因变异对拉米夫定耐药的影响。方法:收集接受拉米夫定(100/mg)初治2年内耐药的26例(耐药组)和2年内无耐药的16例(对照组)慢性乙型肝炎患者治疗基线的血清标本,采用型特异性多引物对巢式PCR法检测HBV基因型,PCR产物直接测序技术检测治疗基线HBV的BCP区和PC区变异位点,对发生频率较高的两组位点变异进行统计分析。结果:HBV BCP/前C区突变中,耐药组与对照组在点突变A1762T(38.48%vs 68.75%,P>0.05),G1764A(26.9%vs 50%,p>0.05)和G1896A(19.23%vs 18.75%,p>0.05)无明显差异;耐药组在点突变C1799G(0%vs 43.75%,p<0.05),T1802C(0%vs 18.75%,p<0.05),G1838A(0%vs 25%,p<0.05),A1846C(0%vs 37.5%,p<0.05),C1856T(0%vs 31.5%,p<0.05),G1 888A(0%vs 25%,p<0.05)明显低于对照组。结论:治疗基线HBV BCP区的A1762T/G1764A变异和前C区的G1896A变异对LAM的2年疗效影响不大;治疗基线HBV BCP区的C1799G、T1802C、G1838A、A1846C的变异和前C区的C1856T、G1888A的变异可能是接受拉米夫定初治患者获得长期维持应答的预测因素之一。

关键词：拉米夫定耐药 HBV BCP BCP

来源：评论

学校读者我要写书评

暂无评论

Rescue therapy for HBeAg-positive chronic hepatitis B patients with resistance to lamivudine plus adefovir

Rescue therapy for HBeAg-positive chronic hepatitis B patien...

引用

第三届全国病毒性肝炎慢性化重症化基础与临床研究进展学术会议

作者：郭世民 Dengming He Maoshi Li Peng Zhu Jie Wang Yuming Wang Institute of Infectious Diseases Southwest HospitalThird Military Medical University

Objective Patients who have not obtained the effective suppression of hepatitis B virus(HBV) replication cannot have an improvement in liver *** aimed to explore the differences of several rescue therapy for patients with resistance to lamivudine plus adefovir. Methods A total of 101 patients(male 87) who had not obtained viral response by lamivudine plusadefovirfor more than two years from January 2005 to January 2011 were included in this study, including virological breakthrough 62 cases and partial response 39 *** DNAbefore rescue therapy was 3.72±1.24 log10 IU/*** therapy:(A) lamivudine 100mg + adefovir 20mg(27 cases);(B) entecavir 0.5mg + adefovir 10/20mg(50 cases);(C) entecavir 0.5mg + tenofovir 300mg (11 cases);(D) pegylated-interferon or interferon(13 cases).Alanine aminotransferase(ALT),HBV DNA,HBV markers,and creatinine were detected every 3 *** period of rescue therapy was 12(9-18) months. Results The proportion of virological response in A,B,C,and D was 81.4%,86%,100%,and 30.7%, *** rate of HBeAg seroconversion was 2.9%.In patients with virological response,the rate of biochemistry response was 80.4%(70/87).In 10 cases with entecavir 0.5mg + adefovir 20mg who did not obtain virological response by entecavir 0.5mg + adefovir 10mg,seven cases obtained virological *** 60 patients with adefovir 20 mg,only one patient had occurred evaluation of creatinine at the time point of a follow-up of 24 months. Conclusions The combination of entecavir plus tenofovir is the prefer strategy of rescue therapy for HBeAg-positive chronic hepatitis B with resistance to lamivudine plus *** strategy of adefovir 20 mg is considerable for its safe and *** strategy of interferon is not suitable for its poor response.

关键词： HBeAg Rescue therapy for HBeAg-positive chronic hepatitis B patients with resistance to lamivudine plus adefovir

来源：评论

学校读者我要写书评

暂无评论

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案：

请选择收藏分类：

通借通还

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：